Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name SAF-189s
Synonyms
Therapy Description

SAF-189s is an ALK and ROS1 inhibitor that is able to penetrate the central nervous system, which potentially reduces tumor cell proliferation and tumor growth (PMID: 32918045).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SAF-189s Foritinib Succinate|SAF189s|SAF 189s ALK Inhibitor 32 ROS1 Inhibitor 20 SAF-189s is an ALK and ROS1 inhibitor that is able to penetrate the central nervous system, which potentially reduces tumor cell proliferation and tumor growth (PMID: 32918045).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 S1986Y Advanced Solid Tumor predicted - sensitive SAF-189s Preclinical - Biochemical Actionable In a preclinical study, SAF-189s inhibited kinase activity of a transformed cell line expressing ROS1 S1986Y in culture (PMID: 32918045). 32918045
ALK rearrange lung non-small cell carcinoma predicted - sensitive SAF-189s Phase Ib/II Actionable In a Phase I/II trial, SAF-189s was well tolerated in ALK-positive non-small cell lung cancer patients, and resulted in a disease control rate (DCR) of 100% and median progression-free survival (PFS) of 33.1 mo in ALK inhibitor (ALKi)-naive and 22.1 mo in ALKi-pretreated patients in Phase I, and a DCR of 98.1% and 88.5%, and objective response rate of 92.3% and 65.4%, in ALKi-naive or crizotinib-pretreated patients, respectively, in Phase II (J Clin Oncol 40, 2022 (suppl 16; abs 9076); NCT04237805). detail...
ROS1 L2026M Advanced Solid Tumor predicted - sensitive SAF-189s Preclinical - Biochemical Actionable In a preclinical study, SAF-189s inhibited kinase activity of a transformed cell line expressing ROS1 L2026M in culture (PMID: 32918045). 32918045
ROS1 D2033N Advanced Solid Tumor predicted - sensitive SAF-189s Preclinical - Biochemical Actionable In a preclinical study, SAF-189s inhibited the kinase activity of a transformed cell line expressing ROS1 D2033N in culture (PMID: 32918045). 32918045
ROS1 G2032R Advanced Solid Tumor predicted - sensitive SAF-189s Preclinical - Biochemical Actionable In a preclinical study, SAF-189s inhibited kinase activity of a transformed cell line expressing ROS1 G2032R in culture (PMID: 32918045). 32918045
ROS1 S1986F Advanced Solid Tumor predicted - sensitive SAF-189s Preclinical - Biochemical Actionable In a preclinical study, SAF-189s inhibited kinase activity of a transformed cell line expressing ROS1 S1986F in culture (PMID: 32918045). 32918045

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries


Additional content available in CKB BOOST